SHARE

Celsion Corporation (NASDAQ:CLSN) has recently announced the latest translational data from the OVATION study of the Phase 1b dose clinical trials that combined GEN-1, Company’s 1L-12 gene-mediated immunotherapy, together with standard care for treatment of the lately-diagnosed patients of Stage 3 and 4 ovarian cancer. The patients went through the neoadjuvant chemotherapy (NACT) and afterwards take the interval debulking surgery.

The translational research data was analyzed with the leading immune-oncology specialists from Roswell Park Cancer Institute. The key translational data from the first 12 of the 15 participants were summarized as follows:

  • The changes in the stimulated immune cytokines, pro-tumor VEGF, and IFN- γ levels. The tracked immunological changes were consistent and were in line with the IL-12 based mechanism.
  • The effects examined in IHC analysis were reported to be decreasing in the mass of the immunosuppressive T-cell signals including the FoxP3, PD-1, PDL-1, and IDO-1) ns an increase in the CD8+cells in the tumor
  • The CD8+ cells to immunosuppressive ratio increased gradually by 75% in patients proposing an entire shift in tumor surroundings following the treatment with GEN-1. The increase in CD8+ cells is an indication and a great predictor of an overall improvement.

The findings shows that GEN-1 is biologically active in the ovarian cancer patients and can develop a dramatic change in the tumor microenvironment by promoting the pro-immune T-cell population.

According to Dr. Khursheed Anwer, the executive vice president and chief science officer at Celsion, the diverse immunological shift in the confined tumor environment is a clinical indication that warrants continuous development of GEN-1 and IL-12 immunotherapy as a possible adjuvant in the first and second phases of ovarian cancer.

In addition, the pro-immune changes in the cancer disease microenvironment also support the findings when GEN-1 is combined with other interesting immune-oncology therapies such as the adaptive T-cell and other check-point inhibitors.

Celsion had previously announced updates of the research findings from its OVARIAN study presented to the American Society of Clinical Oncology in June.

This is Default Discalimer. Please update this from the Intrinio Plugin setting page

LEAVE A REPLY